Eficácia da terapia Anti-IgE no controle da asma

Serpa, Faradiba Sarquis; Piana, Mariana Pando; Braga Neto, Firmino; Campinhos, Fernanda Lugão; Silveira, Marina Gaburro da; Chiabai, Joseane; Zandonade, Eliana.
Braz. j. allergy immunol ; 2(4): 147-153, July-Aug.2014.
Artículo en Portugués | LILACS | ID: lil-775994

Documentos relacionados

  1. Eosinophil to lymphocyte ratio may predict OCS reduction and change in quality of life (AQLQ) resulting from asthma biological treatment.
  2. Severe non-atopic asthma: omalizumab can reduce severe asthma exacerbations.
  3. [Evaluation of the effectiveness of bronchial thermoplasty in patients with severe asthma in the real world two years after bronchial thermoplasty treatment].
  4. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
  5. [Efficacy of omalizumab in the treatment of eosinophilic granulomatous polyangiitis with asthma as the first symptom].
  6. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
  7. Anti-IL-5 therapies for asthma.
  8. Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial.
  9. Which patients with COPD need an inhaled corticosteroid?
  10. Changes after 12 years of follow-up severe asthma patients cohort: higher obstruction and comorbidities, but significant better quality of life.